Copied
 
 
2022, DKK
08.05.2023
Bruttoresultat

979'

Primær drift

-7.703'

Årets resultat

-6.018'

Aktiver

13.540'

Kortfristede aktiver

12.730'

Egenkapital

10.488'

Afkastningsgrad

-57 %

Soliditetsgrad

77 %

Likviditetsgrad

423 %

Resultat
08.05.2023
Årsrapport
2022
08.05.2023
2021
23.06.2022
2020
08.07.2021
2019
18.08.2020
2018
31.05.2019
2017
22.05.2018
Nettoomsætning5.849.0772.026.8901.651.8401.159.8991.054.588225.706
Bruttoresultat979.147125.4661.068.699540.640101.193192.452
Resultat af primær drift-7.702.525-3.567.351-3.993.238-2.740.990-2.693.521-376.998
Indtægter af kapitalandele (tilknyttede og associerede) 000000
Finansielle indtægter11.09964637.927527.9510
Finansieringsomkostninger000000
Andre finansielle omkostninger-21.549-60.748-30.648-13.527-92-8.002
Resultat før skat-7.712.975-3.627.453-3.985.959-2.754.465-2.685.662-385.000
Resultat-6.017.830-2.829.711-3.109.048-2.148.483-2.094.816-300.300
Forslag til udbytte000000
Aktiver
08.05.2023
Årsrapport
2022
08.05.2023
2021
23.06.2022
2020
08.07.2021
2019
18.08.2020
2018
31.05.2019
2017
22.05.2018
Kortfristede varebeholdninger000000
Kortfristede tilgodehavender fra salg og tjenesteydelser 3.336.1441.107.0791.942.941885.524715.200131.625
Likvider9.393.5116.645.7539.001.2455.555.5743.606.2252.741.206
Kortfristede aktiver12.729.6557.752.83210.944.1866.441.0984.321.4252.872.831
Immaterielle aktiver og goodwill000000
Finansielle anlægsaktiver41.52016.29316.29316.29315.8180
Materielle aktiver769.17400000
Langfristede aktiver810.69416.29316.29316.29315.8180
Aktiver13.540.3497.769.12510.960.4796.457.3914.337.2432.872.831
Aktiver
08.05.2023
Passiver
08.05.2023
Årsrapport
2022
08.05.2023
2021
23.06.2022
2020
08.07.2021
2019
18.08.2020
2018
31.05.2019
2017
22.05.2018
Forslag til udbytte000000
Egenkapital10.488.1006.505.9309.335.6415.444.6893.604.8842.699.700
Hensatte forpligtelser40.95200000
Langfristet gæld til banker000000
Anden langfristet gæld0499.519489.744158.89400
Leverandører af varer og tjenesteydelser1.954.431346.505182.474325.238259.74814.048
Kortfristede forpligtelser3.011.297763.6761.135.094853.808732.359173.131
Gældsforpligtelser3.011.2971.263.1951.624.8381.012.702732.359173.131
Forpligtelser3.011.2971.263.1951.624.8381.012.702732.359173.131
Passiver13.540.3497.769.12510.960.4796.457.3914.337.2432.872.831
Passiver
08.05.2023
Nøgletal
08.05.2023
Årsrapport
2022
08.05.2023
2021
23.06.2022
2020
08.07.2021
2019
18.08.2020
2018
31.05.2019
2017
22.05.2018
Afkastningsgrad -56,9 %-45,9 %-36,4 %-42,4 %-62,1 %-13,1 %
Dækningsgrad 16,7 %6,2 %64,7 %46,6 %9,6 %85,3 %
Resultatgrad -102,9 %-139,6 %-188,2 %-185,2 %-198,6 %-133,0 %
Varelagerets omsætningshastighed Na.Na.Na.Na.Na.Na.
Egenkapitals-forretning -57,4 %-43,5 %-33,3 %-39,5 %-58,1 %-11,1 %
Payout-ratio Na.Na.Na.Na.Na.Na.
Gældsdæknings-nøgletal Na.Na.Na.Na.Na.Na.
Soliditestgrad 77,5 %83,7 %85,2 %84,3 %83,1 %94,0 %
Likviditetsgrad 422,7 %1.015,2 %964,2 %754,4 %590,1 %1.659,3 %
Resultat
08.05.2023
Gæld
08.05.2023
Årsrapport
08.05.2023
Nyeste:01.01.2022- 31.12.2022(offentliggjort: 08.05.2023)
Information om virksomhedens regnskabsklasse:The annual report of BiOrigin ApS for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.
Beretning
08.05.2023
Dato for ledelsens godkendelse af årsrapporten:2023-04-24
Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Going concern The Company’s operations and activities are currently loss making and the Company is financed via funds from its shareholder, Novo Holdings A/S, who periodically contributes capital to the Company in the form of capital increases. Considering the Company’s net current assets and funds obtained from the capital increase in March 2023, as discussed below, management assesses that the company can fund its activities as planned at least through 31 December 2023. On this basis the financial statements are prepared on a going concern assumption.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of BiOrigin ApS for the financial year 1 January - 31 December 2022.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:BiOrigin ApS' primary activity consists of rendering strategic and operational support to the establishment and management of early-stage life sciences companies, primarily within the Novo Seeds portfolio, to help them steer through the critical start-up and subsequent growth phase. The Company is fully owned by Novo Holdings A/S. In 2022 BiOrgin expanded the number of Entrepreneurs in Residence in order to accelerate company creation and value creation in the Novo Seeds investment portfolio. Also, BiOrigin Labs was established with the purpose of identifying more compelling technologies and to validate and accelerate new therapeutic concepts.